117 related articles for article (PubMed ID: 20196613)
1. Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).
Hughes RO; Rogier DJ; Jacobsen EJ; Walker JK; Macinnes A; Bond BR; Zhang LL; Yu Y; Zheng Y; Rumsey JM; Walgren JL; Curtiss SW; Fobian YM; Heasley SE; Cubbage JW; Moon JB; Brown DL; Acker BA; Maddux TM; Tollefson MB; Mischke BV; Owen DR; Freskos JN; Molyneaux JM; Benson AG; Blevis-Bal RM
J Med Chem; 2010 Mar; 53(6):2656-60. PubMed ID: 20196613
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.
Hughes RO; Walker JK; Rogier DJ; Heasley SE; Blevis-Bal RM; Benson AG; Jacobsen EJ; Cubbage JW; Fobian YM; Owen DR; Freskos JN; Molyneaux JM; Brown DL; Acker BA; Maddux TM; Tollefson MB; Moon JB; Mischke BV; Rumsey JM; Zheng Y; MacInnes A; Bond BR; Yu Y
Bioorg Med Chem Lett; 2009 Sep; 19(17):5209-13. PubMed ID: 19631533
[TBL] [Abstract][Full Text] [Related]
3. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Linget JM; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4533-42. PubMed ID: 14521415
[TBL] [Abstract][Full Text] [Related]
4. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4525-32. PubMed ID: 14521414
[TBL] [Abstract][Full Text] [Related]
5. Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system.
Hughes RO; Walker JK; Cubbage JW; Fobian YM; Rogier DJ; Heasley SE; Blevis-Bal RM; Benson AG; Owen DR; Jacobsen EJ; Freskos JN; Molyneaux JM; Brown DL; Stallings WC; Acker BA; Maddux TM; Tollefson MB; Williams JM; Moon JB; Mischke BV; Rumsey JM; Zheng Y; Macinnes A; Bond BR; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4092-6. PubMed ID: 19539468
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism.
Menniti FS; Ren J; Coskran TM; Liu J; Morton D; Sietsma DK; Som A; Stephenson DT; Tate BA; Finklestein SP
J Pharmacol Exp Ther; 2009 Dec; 331(3):842-50. PubMed ID: 19729580
[TBL] [Abstract][Full Text] [Related]
7. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
[TBL] [Abstract][Full Text] [Related]
8. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL
J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
[TBL] [Abstract][Full Text] [Related]
11. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
13. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: part II.
Das S; Shelke DE; Harde RL; Avhad VB; Khairatkar-Joshi N; Gullapalli S; Gupta PK; Gandhi MN; Bhateja DK; Bajpai M; Joshi AA; Marathe MY; Gudi GS; Jadhav SB; Mahat MY; Thomas A
Bioorg Med Chem Lett; 2014 Aug; 24(15):3238-42. PubMed ID: 24980052
[TBL] [Abstract][Full Text] [Related]
15. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.
Bunnage ME; Mathias JP; Wood A; Miller D; Street SD
Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784
[TBL] [Abstract][Full Text] [Related]
16. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
[TBL] [Abstract][Full Text] [Related]
17. New orally active PDE4 inhibitors with therapeutic potential.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
[TBL] [Abstract][Full Text] [Related]
18. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
[TBL] [Abstract][Full Text] [Related]
19. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.
Burgey CS; Robinson KA; Lyle TA; Sanderson PE; Lewis SD; Lucas BJ; Krueger JA; Singh R; Miller-Stein C; White RB; Wong B; Lyle EA; Williams PD; Coburn CA; Dorsey BD; Barrow JC; Stranieri MT; Holahan MA; Sitko GR; Cook JJ; McMasters DR; McDonough CM; Sanders WM; Wallace AA; Clayton FC; Bohn D; Leonard YM; Detwiler TJ; Lynch JJ; Yan Y; Chen Z; Kuo L; Gardell SJ; Shafer JA; Vacca JP
J Med Chem; 2003 Feb; 46(4):461-73. PubMed ID: 12570369
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase-5 inhibition synergizes rho-kinase antagonism and enhances erectile response in male hypertensive rats.
Wilkes N; White S; Stein P; Bernie J; Rajasekaran M
Int J Impot Res; 2004 Apr; 16(2):187-94. PubMed ID: 15073608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
